Search | Clinical Trials Finder

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%, Latanoprost Ophthalmic Solution 0.005%; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions: iStent infinite trabecular micro-bypass system model iS3, iDose TR (Travoprost intracameral Implant) 75mcg; Device · Drug
Lead sponsor: Jonathon Myers; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma
Interventions: iStent Inject (GTS400), Cataract Surgery; Device · Procedure
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 22
States / cities: Rogers, Arkansas • Petaluma, California • Parker, Colorado + 19 more

Conditions: Primary Open Angle Glaucoma (POAG)
Interventions: Direct Selective Laser Trabeculoplasty; Device
Lead sponsor: Select Eye Care; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Elkridge, Maryland

Conditions: Sturge-Weber Syndrome (SWS), Glaucoma, Glaucoma Congenital, Ocular Hypertension
Interventions: QLS-101ophthalmic solution 1%, QLS-101ophthalmic solution 2%; Drug
Lead sponsor: Qlaris Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: AR-12286 0.5% Ophthalmic Solution; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Diego, California

Conditions: Glaucoma, Glaucoma, Open Angle
Interventions: SOLX Titanium Sapphire Laser (TiSaLT), Argon Laser Trabeculoplasty (ALT); Device
Lead sponsor: SOLX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 5
States / cities: Petaluma, California • Tampa, Florida • New York, New York + 2 more

Conditions: Normal Tension Glaucoma
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Ocular Hypertension, Open Angle Glaucoma
Interventions: Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution, Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 489 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 30
States / cities: Dothan, Alabama • Phoenix, Arizona • Garden Grove, California + 25 more

Conditions: Open Angle Glaucoma, Primary Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma in Both Eyes
Interventions: Glaucoma and Cataract Surgery; Procedure
Lead sponsor: Wills Eye; Other
Eligibility: 40 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma, Glaucoma, Open-Angle, Glaucoma; Drugs, Droopy Eyelid, Ptosis, Glaucoma, Primary Open Angle
Interventions: brimonidine tartrate ophthalmic solution 0.025%, sterile balanced saline solution; Drug · Other
Lead sponsor: Tulane University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost SR, LUMIGAN; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Dothan, Alabama • Newport Beach, California • Roswell, Georgia + 3 more

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: QLS-101, Timolol Maleate; Drug
Lead sponsor: Qlaris Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Albany, Georgia

Conditions: Open Angle Glaucoma
Interventions: Micropulse Laser Trabeculoplasty, Selective Laser Trabeculoplasty; Device
Lead sponsor: David Belyea; Other
Eligibility: Not listed
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Normal Tension Glaucoma
Interventions: Netarsudil Ophthalmic, Bimatoprost Ophthalmic; Drug
Lead sponsor: Salus University; Other
Eligibility: 21 Years to 89 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Vestal, New York

Conditions: Intraocular Pressure (IOP), Healthy Adult
Interventions: Eplerenone, Microcrystalline Cellulose NF (placebo); Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Primary Open Angle Glaucoma (POAG), Primary Open Angle Glaucoma of Both Eyes, Primary Open-Angle Glaucoma, Unspecified Eye, Ocular Hypertension (OHT)
Interventions: Experimental: QLS-111 ophthalmic solution, (0.015%), Experimental: QLS-111 ophthalmic solution, (0.03%), Experimental: QLS-111 ophthalmic solution, (0.075%), QLS-111 ophthalmic vehicle solution; Drug · Other
Lead sponsor: Qlaris Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Roswell, Georgia

Conditions: Glaucoma, Open Angle, Low Risk, Ocular Hypertension, Glaucoma Suspect
Interventions: Mercury™ Multi-Pressure Dial (MPD) Experimental Goggle, Mercury™ Multi-Pressure Dial (MPD) Placebo Goggle; Device
Lead sponsor: Vance Thompson Vision; Other
Eligibility: 22 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Glaucoma, Open-Angle
Interventions: Negative Pressure Treatment via the Mercury Multi-Pressure Dial; Device
Lead sponsor: Equinox; Industry
Eligibility: 22 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Chicago, Illinois • Sioux Falls, South Dakota • San Antonio, Texas

Conditions: Primary Open-angle Glaucoma, Ocular Hypertension
Interventions: LX7101 (0.125%), LX7101 (0.25%), LX7101 Vehicle; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 5
States / cities: Morrow, Georgia • Memphis, Tennessee • Austin, Texas + 2 more

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Glaucoma, Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Glaucoma, Glaucoma, Open Angle
Interventions: SOLX Gold Shunt GMS-plus, Ahmed FP7 Glaucoma Valve; Device
Lead sponsor: SOLX, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 9
States / cities: Petaluma, California • Littleton, Colorado • Tampa, Florida + 6 more

Conditions: Elevated Intraocular Pressure
Interventions: Latanoprost ophthalmic solution, 0.005%, TC-002 latanoprost ophthalmic solution, 0.005%; Drug
Lead sponsor: TearClear Corp; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 20
States / cities: Garden Grove, California • Glendale, California • Mission Hills, California + 16 more

Search by objective public record fields.

Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma

GTS400 Stent Implantation in Conjunction With Cataract Surgery in Subjects With Open-angle Glaucoma

Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Eye Pressure in Non-Caucasian Patients With Open Angle Glaucoma

A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101

24-hour Efficacy of AR-12286

SOLX Titanium Sapphire Laser for Trabeculoplasty

IOP Lowering Effects of Topical Anesthetics Used Frequently in the Ophthalmology Clinic

Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction

IOP and Medication Reduction in MIGS Procedures

The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).

Micropulse Laser Trabeculoplasty (MLT) Versus Selective Laser Trabeculoplasty (SLT) for Treatment of Open Angle Glaucoma

Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma

Eplerenone and IOP in Healthy Adults

Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients

Effect of Negative Pressure on Pattern Electroretinography Readings

Negative Pressure Applied by the Equinox MPD for Severe Open Angle Glaucoma

Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Diurnal and Nocturnal Effect of Travatan With SofZia Preservative on Intraocular Pressure and Ocular Perfusion Pressure

Changes in Eye Pressure and Anterior Chamber Depth With Oral Endothelin Antagonist Therapy

SOLX Gold Shunt Versus Control Implant: Randomized Trial for Refractory Glaucoma

Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure